SEC Form 4 · accession 0000899243-18-008989
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Southwell
Director
Period of report
Mar 30, 2018
Accepted (ET)
Mar 30, 2018 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.25 | Mar 30, 2018 | A | 12,146 | A | — | Mar 30, 2028 | Common Stock | 12,146 | 12,146 | D |
Explanation of responses
- F1The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following March 30, 2018, subject to the Reporting Person's continued service as a director through the applicable vesting dates.